Introduction
============

The use of serological tests to measure antibodies against malaria has been advocated as an adjunct approach to improve the detection of transmission dynamics ([@B11]; [@B44]; [@B22]). This is particularly useful in low transmission settings, where the detection of low-density infections is a major challenge ([@B30]; [@B56]). Due to the longevity of antibody responses they cannot be used as a diagnostic for current infections, but at the population-level, when combined with age, they represent historical and recent transmission ([@B13]; [@B11]; [@B44]). Antibody metrics are less influenced by fluctuations in infection rates between seasons, and where infection rates fall to near elimination, they can help determine whether there is any remaining ongoing transmission. The discovery of antigenic markers that correlate with recent microscopic infection shows promise in the context of detecting recent malaria transmission patterns more sensitively (i.e., up to 1 year) ([@B16]). However, it remains largely unknown which antigens most reliably induce measurable antibody responses to allow accurate detection of recent exposure to low-density infections.

The identification of antibody responses, and their corresponding antigen targets, following low-density infections in endemic settings is challenging, as the history of previous exposure is often difficult to determine. Longitudinal studies have demonstrated the acquisition of antibodies following asymptomatic infection in endemic areas and suggest that antibodies to some antigens might be more sensitive markers of recent exposure ([@B26]). A powerful model to examine this is using controlled human malaria infections (CHMI) in which healthy volunteers are infected via mosquito bites ([@B37]), parenteral injection with sporozoites ([@B1]) or infected red blood cells ([@B34]). Parasite densities are monitored intensely and remain low as treatment is provided either at the first microscopy-detectable parasitemia, or even earlier at levels detectable only by qPCR ([@B51]). CHMI studies in non-endemic (reviewed in ([@B38])) and endemic ([@B41]; [@B18]) settings generally aim to determine correlates of immune protection or test vaccination strategies ([@B1]). Therefore, responses against mainly pre-erythrocytic antigens have been studied ([@B15]; [@B28]; [@B32]), some of which have been suggested as markers of recent parasite exposure ([@B28]). However, few have studied antibody responses in previously naïve control groups and only a small number of antigenic targets have been analyzed using enzyme-linked immunosorbent (ELISA) or multiplex bead assays ([@B48]; [@B29]; [@B19]; [@B8]).

Protein microarrays enable the simultaneous detection of antibody responses to hundreds of antigens to identify biomarkers related to protection or exposure ([@B7]). Antigen production for these arrays have mostly used the *in vitro* translation/transcription (IVTT) open reading frame (ORF) method -- a polymerase chain reaction (PCR)-based approach that generates large numbers of putative proteins ([@B12]). In this study, we use a custom-made protein microarray based on purified recombinant malaria antigens which was enriched for antigens associated with recent exposure. Using this array, we aimed to identify immunogenic targets associated with recent low-density *Plasmodium falciparum* infections in previously malaria-naïve CHMI participants.

Materials and Methods {#s1}
=====================

Study Population
----------------

Fifty-four malaria naïve participants \[based on patient history and lack of antibody responses to asexual parasite lysate ([@B50])\] from eight CHMI studies were included (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). The study population and sampling frame have been described in detail elsewhere ([@B3], [@B4],[@B5]; [@B1]; [@B50]; [@B36]). In short, volunteers were infected by exposure to five laboratory reared *Anopheles* mosquitoes infected with *P. falciparum* sporozoites of the well characterized NF54 strain, its clone 3D7, or the more recently characterized NF135.C10 ([@B46]) or NF166.C8 ([@B25]) strains. Citrate plasma samples for antibody detection were selected at three time points: 1 day pre-challenge (C~-1~), 21 or 35 days after challenge (median 30 days; C~+30~) and 64, 140, or 213 days after challenge (median 115 days; C~+115~). All available samples were analyzed.

Ethics Statement
----------------

All clinical trials were carried out in accordance with Good Clinical Practice guidelines and were prospectively registered at [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT numbers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). All subjects gave written informed consent prior to participation in accordance with the Declaration of Helsinki. Each clinical trial protocol was approved by the Central Committee on Research Involving Human Subjects (CCMO) of the Netherlands (reference numbers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Study 8 was also approved by the Western Institutional Review Board (WIRB) in the United States.

Parasite Detection
------------------

Volunteers were monitored for the development of symptoms and blood-stage parasites once or twice daily after infection. In studies 1--4 and 8 (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) parasitemia was treated when detectable by thick blood smear. Blood smears were read according to a standardized protocol for CHMI studies ([@B4]), in which slides are scored as positive if at least two parasites were seen in 0.5 μl of blood (threshold of ∼4 parasites/μl). A second independent microscopist confirmed positivity. In these studies qPCR was performed on all blood samples according to a previously published protocol ([@B39]). In studies 5--7, qPCR was performed prospectively, and volunteers were treated when parasitemia reached the predetermined threshold of 0.1 parasites/μl ([@B51]). In study 8, some volunteers had a recrudescent infection after initial subcurative treatment ([@B36]).

Protein Microarray
------------------

The IgG responses to 40 antigenic targets, all blood-stage related except for one (CSP), were determined using a custom-made protein microarray (see Supplementary Table [S2](#SM2){ref-type="supplementary-material"} for antigen details). Protein preparations at a concentration of 100 μg/μl of protein in printing buffer (ArrayJet, Scotland) were spotted onto nitrocellulose coated slides (Grace Bio-Labs, United States) with a glycerol-based buffer using the ArrayJet Marathon printer (ArrayJet, Scotland) at the London School of Hygiene and Tropical Medicine (LSHTM). Each slide was sub-divided into 16 arrays with each array consisting of the full complement of antigenic targets printed in duplicate. A standard curve of total human IgG was printed in duplicate within each array (starting concentration 200 μg/ml, fivefold series of 6 points). Samples were processed for IgG detection at the Radboud University Medical Center in Nijmegen. Serum samples were diluted in a deep well at 1:200 in blocking buffer \[Phosphate buffered saline (PBS)/BlockIt buffer (ArrayIt Corporation, United States) 25%\]. The printed nitrocellulose slides were placed in multi-well hybridization cassettes (HC; ArrayIt Corporation, United States), blocked with 200 μl of blocking buffer and incubated on a rotary shaker (100 rpm) at room temperature (RT) for 1 h. Slides were washed three times: liquid was removed by sharply flicking buffer into a sink, then 200 μl of wash buffer (PBS/Tween 0.05%) was immediately added and the HC placed on the rotary shaker for 2 min. After the final wash, wash buffer was aspirated using a multichannel pipette one column at the time and 100 μl of test samples was added immediately to avoid drying of the nitrocellulose slides. Participant samples, two positive control pools of hyper-immune sera (three repeats of a Ugandan and four repeats of a Tanzanian pool) and one blank (i.e., blocking buffer only) were distributed over twelve slides. Time points from the same participants were grouped on slides where possible to avoid influences of inter-slide variability during assay processing. Slides were incubated for 1 h at RT on the rotary platform. Slides were washed again three times and IgG-specific goat anti-human secondary antibody (Alexa Fluor 633 goat anti-human IgG; Invitrogen) was added in the same manner as the samples at a concentration of 1:1000. Slides were incubated for 1 h at RT on the rotary platform. After a further three washes, slides were dried by centrifuging them at 3000 rpm for 5 min at RT. Slides were stored at +4°C and read 3 days after assay processing at LSHTM using the GenePix 4300A scanner (Molecular Devices, United States) at a wavelength of 635 nm.

Median fluorescence intensity (MFI) was background-corrected (i.e., local reactivity around the spot; bkg) and duplicate measurements were averaged (Pearson's correlation coefficient 0.99, *p* \< 0.001; Supplementary Figure [S1](#SM3){ref-type="supplementary-material"}). MFI-bkg values smaller than or equal to zero, were replaced with the average value of blank responses and log-transformed. Printing variability was minimal, as determined by the coefficient of variation (CV) of the third point of the standard IgG curve. Inter-slide variability was measured at 1.4% CV, while intra-slide variability was measured at \<2.5%. Likewise, assay variability was minimal as shown by the CV of repeated MFI-bkg values of the positive control pools on different slides for GLURP-R2, MSP4 and CSP (associated with high, medium and low antibody responses): 1.5, 0.2, and 5.5% for the Tanzanian pool (*n* = 4), and 0.5, 0.3, and 4.2% for the Ugandan pool (*n* = 3).

Statistical Analyses
--------------------

All statistical analyses were performed in STATA 14 and PRISM 7. Cumulative parasite density was expressed as the log-transformed area under the curve (AUC) for parasite density versus time in days using the *pkexamine* command in STATA with the *trapezoid* option. Only parasite density results up to, and including, the day of curative antimalarial treatment were included. Tertiles were used to categorize low, medium and high cumulative parasite density. Antibody responses (IgG) were expressed as log-transformed MFI-bkg values. The average response of forty-five participants at C~-1~ plus two standard deviations was used as the threshold for seropositivity by antigen. Antibody responses at C~+30~ and C~+115~ were standardized by subtracting the mean and dividing by the standard deviation (SD) of C~-1~ responses. For both, one outlier at baseline for Etramp 4 Ag 2 was removed (log-transformed MFI-bkg over 8). The Cochran-Armitage test was used to test the trend in the proportion of antigenic targets recognized at each time point over categories of cumulative parasite density. Spearman's rank coefficients (ρ) were used to assess the correlation between antibody responses and cumulative parasite density. The level of statistical significance for individual antigens was adjusted according to the Bonferroni correction. Linear regression was used to test the association between participant characteristics and cumulative parasite density.

Results
=======

Cumulative Parasite Density and Peak Parasite Density
-----------------------------------------------------

All 54 CHMI participants developed a blood-stage infection after sporozoite-induced challenge through infective mosquito bites \[median day of first blood-stage parasites detected by qPCR: 7.0, interquartile range (IQR) 6.5--7.0\]. Parasitemias ranged from peak parasite densities below 1 parasites/μl that were treated 7 days post-challenge, to peak densities of 198 parasites/μl that were treated 14 days post-challenge, as well as recrudescent infections that lasted 39 days post-challenge (Figures [1A](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}). The majority of individuals had peak parasite densities under 100 parasites/μl (50/54), with 19% under one parasite/μl (10/54). A statistically significant difference in cumulative parasite density (expressed as the log-transformed area under the curve for parasite density versus time in days) was seen by gender (*p* = 0.011), which disappeared after adjusting for study (*p* = 0.861). The median age was 21 (IQR 19--22) and did not differ between categories of parasite exposure (*p* = 0.541). As expected, a statistically significant increase was seen in peak parasite density with increasing cumulative parasite density (*p* \< 0.001; Table [1](#T1){ref-type="table"} and Figure [1D](#F1){ref-type="fig"}). Participants with higher cumulative parasite density experienced their peak parasite density later during their infection (*p* \< 0.001; Table [1](#T1){ref-type="table"}).

![Parasitemia after controlled human malaria infection over categories of cumulative parasite density **(A--C)** and associated peak parasite densities **(D)**. Tertiles of cumulative parasite density (expressed as the log-transformed area under the curve for parasite density versus time until, and including the day of treatment) were used to categorize low **(A)**, medium **(B)**, and high **(C)**. Peak parasite density is the maximum number of parasites/μl detected during the infection until, and including the day of treatment.](fmicb-09-03300-g001){#F1}

###### 

Characteristics of the study population according to categories of cumulative parasite density.

                                                All participants   Categories of cumulative parasite density                     
  --------------------------------------------- ------------------ ------------------------------------------- ----------------- -------------------
  *N*                                           54                 19                                          17                18
  **Time point^a^** (*N*)                                                                                                        
  -C~-1~                                        45                 15                                          14                16
  -C~+30~                                       45                 17                                          14                14
  -C~+115~                                      32                 8                                           11                13
  Cumulative parasite density^b^ median (IQR)   8.3 (7.0--9.8)     6.2 (4.6--7.4)                              8.7 (8.2--9.2)    10.0 (9.8--10.7)
  Peak parasite density^c^ median (IQR)         6.9 (2.0--31.6)    1.0 (0.3--2.4)                              7.4 (5.1--19.1)   42.6 (22.7--75.4)
  Day of peak parasite density median (IQR)     10.4 (7.0--12.3)   7.0 (7.0--9.3)                              9.6 (7.0--11.5)   12.2 (10.6--13.5)

Categories of cumulative parasite density are based on tertiles of cumulative parasite density. IQR, interquartile range.
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Cumulative parasite density is expressed as the log-transformed area under the curve for parasites/μl versus time in days until the day of treatment. One participant was not treated until day 36, however, this participant did not have a sample available at C
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for antibody detection thus their total cumulative parasite density was used for categorization in this table.

c

Peak parasite density is the maximum number of parasites/μl during the infection until the day of treatment

.

Minimal Number of Antigens to Detect Infection
----------------------------------------------

The kinetics of IgG responses following challenge are shown in Figure [2](#F2){ref-type="fig"}, while Figure [3A](#F3){ref-type="fig"} shows the number of antigenic targets recognized before and after challenge per category of cumulative parasite density. Two participants recognized more than five out of the panel of 40 antigens pre-challenge (C~-1~); 1 month post-challenge (C~+30~) one of these two participants recognized two additional antigens (9 antigens in total) while the other participant recognized thirteen additional antigens (20 antigens in total). For all categories of cumulative parasite density, the peak number of antigens recognized was at C~+30~. The proportion of targets recognized increased over categories of cumulative parasite density (*p* \< 0.001 for C~+30~ and 2--7 months post-challenge; C~+115~). High seroprevalence (i.e., over 80%) was seen against GLURP-R2 (91%, 41/45) and Etramp 5 Ag 1 (82%, 37/45) at C~+30~, and against MSP1-19 at C~+115~ (84%, 27/32). For participants with medium to high cumulative parasite density, all were seropositive to GLURP-R2 and 96% to Etramp 5 Ag 1 (27/28) at C~+30~ (Supplementary Figure [S2](#SM3){ref-type="supplementary-material"}), and 96% responded to MSP1-19 at C~+115~ (23/24). For the lowest category, 77% (13/17) responded to GLURP-R2 and 59% (10/17) to Etramp 5 Ag 1 at C~+30~, and 50% to MSP1-19 at C~+115~ (4/8). Addition of one to two other antigenic targets for this low exposure category at either time point included all participants with an antibody response (see below for one non-responding participant).

![Kinetics of antimalarial antibody responses after controlled human malaria infection. Antibody responses (expressed as log-transformed median fluorescence intensity corrected for background reactivity) are shown over time, starting 1 day pre-challenge. Red dashed lines represent thresholds of seropositivity using the mean plus two standard deviations of pre-challenge responses across 45 participants. For Etramp 4 Ag 2, the outlier at baseline (blue triangle) was removed for the threshold calculation; the blue dashed line represents the threshold if the outlier at baseline was included.](fmicb-09-03300-g002){#F2}

![The number of antigenic targets recognized at three time points **(A)**, standardized antibody responses **(B)** and averaged standardized antibody responses **(C,D)**. In **(A,C,D)** results are shown over tertiles of cumulative parasite density (expressed as the log-transformed area under the curve for parasite density versus time until, and including the day of treatment). In **(A)** results are further categorized over time points post-challenge. An antigen is considered recognized if antibody responses (expressed as log-transformed median fluorescence intensity corrected for background reactivity) were higher than the mean plus two standard deviations (SD) of pre-challenge responses across 45 participants (i.e., seropositive). In **(B--D)** antibody responses were standardized by subtracting the mean of pre-challenge responses across 45 participants and dividing by its SD. In **(B)** standardized antibody responses 30 days post-challenge are ordered by median reactivity on the *x*-axis. Dashed lines represent arbitrary thresholds at 1 SD (red -- top 10 antigenic targets), 2 SD (green -- top 4 antigenic targets) or 3 SD (blue -- top 2 antigenic targets) greater than the mean of pre-challenge responses. In **(C,D)** standardized antibody responses to antigens with a median above these arbitrary thresholds were averaged and are shown 30 days **(C)** and 115 days **(D)** after challenge, using the same color scheme. Average responses across all 40 targets are shown in black.](fmicb-09-03300-g003){#F3}

Strong Correlation Between Cumulative Parasite Density and Antibody Intensity
-----------------------------------------------------------------------------

Responses up to seven SD greater than the mean of C~-1~ responses were seen at C~+30~ for Etramp 5 Ag 1. Other targets associated with high antibody levels at C~+30~ were GLURP-R2, MSP4 and CSP (SD's greater than five recorded). All participants showed a minimum of one SD greater than the mean of C~-1~ responses for GLURP-R2, while for all other antigens zero to negative responses were seen in at least one of the participants (Figure [3B](#F3){ref-type="fig"}). Highly reactive antigens at C~+30~ were those associated with median responses over arbitrary thresholds of three SD (Top 2: Etramp 5 Ag 1 and GLURP-R2), two SD (Top 4: top 2, as well as MSP4 and MSP1-19) or one SD (Top 10: top 4 as well as GLURP-R0, MSP5, SEA-1, CSP, Etramp 4 Ag 2, AMA1) greater than the mean of C~-1~ responses (Table [2](#T2){ref-type="table"}). Standardized antibody responses to these top responding antigens were averaged to represent overall antibody density at C~+30~ (Figure [3C](#F3){ref-type="fig"}) and C~+115~ (Figure [3D](#F3){ref-type="fig"}). Most individual antigenic targets showed moderate correlation with parasite exposure (i.e., Spearman's ρ = 0.50--0.69) except for GLURP-R0 and CSP (not significant at *p* \> 0.00125), while MSP1-19 showed strong correlation (Spearman's ρ = 0.86, *p* \< 0.001), see (Figure [4](#F4){ref-type="fig"}). Overall antibody density of top responding antigens showed a strong correlation with cumulative parasite density at C~+30~ (all 40 antigens: Spearman's ρ = 0.51, while top 4 responding antigens Spearman's ρ = 0.82; *p* \< 0.001) and C~+115~ (all 40 antigens: Spearman's ρ = 0.50, while top 4 responding antigens Spearman's ρ = 0.78; *p* \< 0.001).

###### 

Characteristics of the top 10 antigenic targets associated with the highest antibody responses 30 days post-challenge in controlled human malaria infection participants.

  Gene ID         Description                                          Name            Allele     Location^a^                         AA position   Expression tag   Reference
  --------------- ---------------------------------------------------- --------------- ---------- ----------------------------------- ------------- ---------------- -----------------------------
  PF3D7_0532100   Early transcribed membrane protein 5                 Etramp 5 Ag 1   3D7        iRBC/PVM                            26--111       GST              [@B42]; Tetteh, unpublished
  PF3D7_1035300   Glutamate rich protein R2                            GLURP-R2        F32        Merozoite (Peripheral)              705--1178     His~x6~          [@B47]
  PF3D7_0207000   Merozoite surface protein 4                          MSP4            D10        Merozoite surface (GPI-anchored)    43--107       GST              [@B23]
  PF3D7_0930300   19 kDa fragment of the merozoite surface protein-1   MSP1-19         Wellcome   Merozoite surface (GPI-anchored)    1631--1726    GST              [@B9]
  PF3D7_0423700   Early transcribed membrane protein 4                 Etramp 4 Ag 2   3D7        iRBC/PVM                            76--136       GST              [@B42]; Tetteh, unpublished
  PF3D7_1035300   Glutamate rich protein R0                            GLURP-R0        F32        Merozoite (Peripheral)              94--489       His~x6~          [@B47]
  PF3D7_0206900   Merozoite surface protein 5                          MSP5            3D7        Merozoite surface (GPI-anchored)    147--207      GST              [@B24]
  PF3D7_1021800   Schizont egress antigen 1                            SEA-1           3D7        Schizont/Maurer's cleft             810--1083     GST              [@B35]; Tetteh, unpublished
  PF3D7_0304600   Circumsporozoite protein                             CSP             3D7        Sporozoite surface                  20--373       n/a              [@B20]
  PF3D7_1133400   Apical membrane antigen 1                            AMA1            FVO        Sporozoite/Merozoite (Micronemes)   97--546       His~x6~          [@B10]

GPI, glycosylphosphatidylinositol; PVM, parasitophorous vacuolar membrane; iRBC, infected red blood cell; GST, glutathione S-transferase; kDa, kilodalton; AA, amino acid

.

a

Location information is based on published literature and mass spec proteomic data (plasmodb)

.

![The association between cumulative parasite density and standardized antibody responses. Cumulative parasite density is expressed as the log-transformed area under the curve for parasite density versus time until, and including the day of treatment. Antibody responses (expressed as log-transformed MFI corrected for background reactivity) 30 days post-challenge were standardized by subtracting the mean of pre-challenge responses across 45 participants and dividing by its standard deviation (SD). In **(A--J)** Spearman's ρ and associated *p*-values are shown per antigen. Solid lines and shaded areas are fractional polynomial fits with 95% confidence intervals. In **(K,L)** standardized antibody responses against antigenic targets with a median above arbitrary thresholds of 1 SD (red -- top 10 antigenic targets), 2 SD (green -- top 4 antigenic targets) or 3 SD (blue -- top 2 antigenic targets) greater than the mean of pre-challenge responses, were averaged. Average responses across all forty targets are shown in black. In **(K)** Spearman's ρ for all 40: 0.51, top 10: 0.77, top 4: 0.82, top 2: 0.61; *p* \< 0.001 and in **(L)** all 40: 0.50, top 10: 0.69, top 4: 0.78, top 2: 0.72; *p* \< 0.001.](fmicb-09-03300-g004){#F4}

Participants With Limited Antibody Response
-------------------------------------------

One participant had no demonstrable IgG to any of the 40 malarial antigens tested in samples at either of the post-challenge time points, though tetanus toxoid responses were recorded (log-transformed MFI-bkg values over 7.9 across both time points). For participants with serum samples available at both post-challenge time points, two other participants had an antibody response to only one of the forty antigens at either the C~+30~ or the C~+115~ time point (to CSP or GLURP-R2). The total proportion of individuals with no detectable IgG antibodies at C~+30~ was therefore 4.4% (2/45) and at C~+115~ 6.5% (2/31). These three participants were in the lowest category of cumulative parasite density and had peak parasite densities ≤0.20 parasites/μl.

Discussion
==========

Controlled human malaria infection trials provide unique opportunities to study immune responses after exposure to a known number of malaria-infected mosquitoes and an accurately quantified parasite exposure ([@B38]; [@B40]). We measured antimalarial antibody (IgG) responses in previously malaria naïve individuals from eight CHMI studies using a custom-made protein microarray. We showed that low parasite densities generated detectable IgG responses in 96% of the participants 1 month after challenge, and in 94% two to 7 months after challenge. Even at the low parasite densities recorded in these participants, a strong correlation was seen between cumulative parasite density and the number of antigenic targets recognized as well as the intensity of IgG responses. Immune responses to a subset of proteins including one hypothesized to be associated with recent exposure were developed by nearly all individuals (i.e., GLURP-R2, MSP1-19 and Etramp 5 Ag 1). It is an important observation that exposure to these infections was detected considering the low parasite density range, which would probably have remained undetected by routine microscopy or rapid diagnostic tests (i.e., 50/54 participants had peak parasite densities \<100 parasites/μl while all remained \<200 parasites/μl) ([@B55]; [@B30]; [@B56]).

We assessed IgG reactivity to forty purified recombinant antigens of the *P. falciparum* parasite. All targets were associated with the erythrocytic stage of the parasite life cycle, except for one pre-erythrocytic target (CSP). GLURP-R2, Etramp 5 Ag 1, MSP4 and MSP1-19 were associated with the highest relative antibody responses. Seroprevalence 1 month post-challenge was highest for GLURP-R2 (91%) and Etramp 5 Ag 1 (82%), dropping to approximately two-thirds seropositive two to 7 months post-challenge. Etramp 5 Ag 1 was associated with the highest antibody levels 1 month after challenge relative to pre-challenge responses. This antigen was one of the targets highlighted as a potential marker of recent exposure in a cohort of Ugandan children ([@B16]). Likewise, GLURP-R2 was associated with recent exposure in a Cambodian population ([@B21]). Although we were unable to assess the rate of antibody decay in this study due to the small sample size, the low number of individuals with repeated samples and limited follow up time, high reactivity is evident in this previously non-exposed population. Other hypothesized markers of recent exposure identified by [@B16] were also recognized in this population (42% for CSP and 27% for Etramp 4 Ag 2 1 month post-challenge), whereas HSP40 and GEXP18 were not (\<5%). At 2--7 months after challenge, MSP1-19 was associated with the highest seroprevalence (84%; 27/32). This target also showed the strongest correlation with cumulative parasite density 1 month post-challenge (Spearman's ρ = 0.86, *p* \< 0.001). MSP1-19 has been associated with changes in transmission over time ([@B49]) and in recent transmission ([@B45]). MSP4 was the final target in the top four responding antigens 1 month after challenge, while MSP5 was in the top 10. These antigens were associated with protection against clinical disease in Senegalese ([@B33]), Brazilian ([@B27]), and Vietnamese ([@B53]) populations and warrant further investigation. MSP4 was also strongly associated with recent asymptomatic and symptomatic infections in Kenyan children alongside AMA-1, MSP1-19, and EBA140 RII ([@B26]).

Previous studies describing antibody responses to malaria in CHMI participants concluded that a single CHMI is sufficient to induce production of antibodies directed against sporozoite, liver-stage and cross-stage antigens ([@B40]). In line with our current findings, the magnitude of antibody and memory B-cell responses to cross-stage antigen MSP1-19 was reported to correlate with the degree of parasite exposure (duration and peak density) ([@B6]; [@B14]; [@B28]; [@B52]). The majority of studies examining antibody responses following CHMI focused on antibody responses related to (sterile) protection and identified antigenic targets such as EXP-1 ([@B29]), LSA-1 ([@B15]; [@B28]), TRAP ([@B32]), and CSP ([@B15]; [@B28]; [@B29]; [@B17]), showing some evidence for an increase in responses with increasing parasite exposure. Only a limited number of studies have reported antibody responses to multiple malarial antigenic targets, other than CSP or AMA1 and MSP1-19 alone, in the previously malaria naïve control groups of CHMI trials ([@B48]; [@B29]; [@B19]). [@B29] and [@B19] assessed antibody responses after CHMI in both non-endemic and endemic populations using ELISA ([@B19]). Seropositivity against MSP1-19, Rh5, CSP, and LSA-1 were similar to those we recorded. However, seropositivity against AMA-1 was considerably higher ([@B19]) or non-existent ([@B29]), compared to moderate responses in our study. These differences may be due to differences in assay protocols, strains used \[3D7 ([@B19]) versus FVO\] or the levels of parasite exposure. In both studies, antimalarial antibody responses were induced more efficiently in endemic volunteers compared to non-endemic volunteers, even if baseline responses were the same, indicating the presence of memory B cells in endemic populations ([@B54]). [@B8] reported that the generation of antibodies to blood-stage antigens following CHMI is strongly influenced by expression patterns of microRNA, which are involved in regulation of immune responses, and that microRNA expression patterns vary considerably between individuals. [@B48] explored antibody responses to (multiple regions of) five blood-stage antigenic targets in volunteers from a Dutch CHMI trial using a multiplex bead assay. They found responses in 93% of volunteers 35 days post-challenge, mostly against PfEMP1 (which was not included in our panel) and GLURP-R2, with lower seropositivity against GLURP-R0 and MSP3, similar to our results. They saw no association between PfEMP1 antibody acquisition and parasite load or maximum parasite density ([@B48]). The strong correlations seen in the current cohort are most likely due to the increased range in parasite exposure. In addition to the overlap in these previously described results, we show responses to a range of erythrocytic antigens including those potentially associated with recent infection using a newly developed custom-made protein microarray.

Studying antibody responses following malaria infections in volunteers from non-endemic areas is informative due to difficulties in assessing the exact level and frequency of previous exposure in endemic populations. Genetic and environmental differences between malaria endemic and non-endemic populations make direct translation of these results challenging. Moreover, parasite densities are likely to reach considerably higher levels in natural infections, which in turn would influence the number of antigenic targets recognized and the intensity of existing responses. Nevertheless, an overlap was seen between our results and those from endemic populations for certain antigenic targets \[Etramp 5 ([@B16]), Etramp 4 ([@B16]), CSP ([@B2]; [@B16]), MSP4 ([@B2]; [@B8]; [@B26]), MSP1-19 ([@B26]) and to a lesser extent in our results AMA-1 ([@B43]; [@B26])\], while not for other targets \[GEXP18 ([@B16]), HSP40 ([@B16]), EBA140, EBA175, and MSP2 ([@B43]; [@B8]; [@B26]\]). Overall, it is an important observation that antibody responses could be detected in a previously non-exposed population following such low-density infections. The duration of detectable antibody titres in the current study population, especially after re-infection, is unknown. This information is of use for validation of these targets in sero-surveillance aiming to generate proxy estimates of incidence for transmission monitoring. Further assessment of antibody kinetics following infection (i.e., assessing time since infection) using these antigenic targets is essential. Although all participants were previously naïve for malaria, we saw reactivity to some of the included targets at the pre-challenge time point (i.e., Etramp 4 Ag 2) potentially due to cross-reactivity with antigens from other pathogens. Likewise, responses to AMA1 and MSP1-19 were seen in some of the malaria naïve United Kingdom adults pre-challenge at similar concentrations to those detected at C~+30~ ([@B19]). Using a two-standard deviation rule to define the threshold of positivity has its limitations; by default, this will cause some participants to be defined as seropositive pre-challenge (i.e., approximately 2.5%). One participant remained undetected for IgG responses against the panel of 40 antigens evaluated. This may be due to the very low exposure to malaria parasites as their peak parasite density was the lowest recorded (0.15 parasites/μl) and the duration of their infection as detected by qPCR was 1 day. Two other participants with limited antibody responses recorded (i.e., to one of the antigens in the panel at only one of the time points) had peak parasite densities of ≤0.20 parasites/μl. Furthermore, the panel of targets evaluated is finite and there may be antigens not yet expressed that would have induced a detectable immune response in these participants. Lastly, IgM responses were not evaluated in this study, which may also have been present in these participants.

Conclusion
==========

Antibody responses to erythrocytic antigens were detectable following low-density experimental *P. falciparum* infections in nearly all volunteers. This included antigenic targets potentially related to recent infection ([@B16]) as well as well-known targets such as AMA1, MSP1-19, and CSP. Detecting exposure to recent infections below the detection limit of conventional diagnostics is essential to interrupt transmission ([@B31]; [@B22]), especially in low transmission and elimination settings where the majority of infections are of low-density ([@B30]; [@B56]). We showed a strong dose-response relationship between cumulative parasite density and antibody density across multiple targets. Moving forward, a selection of 4--5 targets could be combined in a field-based assay such as an ELISA to rapidly assess remaining transmission in (near-) eliminating settings. This would be advantageous compared to measuring infection rates, as PCR-based techniques are more costly and labor-intensive, require larger sample sizes in low transmission settings, are more sensitive to fluctuations in parasite densities during an infection and overall rates between seasons. Ultimately, our findings require validation in endemic populations to define the minimum set of antigens needed to reliably detect exposure to natural infections.
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